More recently, imaging techniques such as multiparametric magnetic resonance imaging (mpMRI) and prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT) have evaluated as a potential tool for staging prostate cancer in men before radical treatment. Here, FOLH1 is linked to prostate cancer.